Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | The recent expanded FDA approval of cilta-cel and ide-cel into earlier lines of myeloma treatment

Sergio Giralt • 16 Apr 2024
EBMT 2024
Multiple Myeloma CAR-T Ciltacabtagene autoleucel Idecabtagene vicleucel

Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, shares his thoughts on the recently expanded approval of ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) into earlier lines of treatment for patients with multiple myeloma. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Sergio Giralt

0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:12
An update in cellular therapies: gene editing for SCD and immunotherapies for MM
Sergio Giralt • 8 Dec 2023
0:59
The role of radioimmunoconjugates in AML treatment: insights from the SIERRA trial
Sergio Giralt • 8 Dec 2023

Related Videos

1:50
The recent expanded approval of cilta-cel into earlier lines of myeloma therapy
Roberto Mina • 23 Apr 2024
2:13
Frontline treatment of transplant eligible patients with myeloma: current approach & future changes
Karthik Ramasamy • 28 Apr 2024
History and upcoming projects of the MMRF
Hearn Jay Cho et al. • 3 May 2024
7:50
The ESC guidelines on cardio-oncology: incorporating the guidelines into clinical practice
Alexander Lyon • 25 Apr 2024
The content of VJHemOnc is intended for healthcare professionals